-
2024-511084-28-00
11
2026-01-12
Hypertrophic Cardiomyopathie
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2025-521128-31-00
9
2025-12-18
Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
-
2024-517653-27-00
4
2025-12-17
Prostate Cancer
-
2024-514763-25-01
1
2025-12-04
spinocerebellar ataxia type 2
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521398-15-00
5
2025-12-04
Immune system diseases
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-517091-38-00
3
2025-11-25
Head and neck squamous cell carcinoma
-
2024-519048-33-00
10
2025-11-25
resected pancreatic adenocarcinoma
-
2024-519779-24-00
4
2025-11-25
VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC) syndr
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2023-510568-11-00
9
2025-11-18
High grade brain tumors
-
2024-512849-17-00
5
2025-11-14
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma
-
2024-517316-29-00
4
2025-11-07
Unresectable stage III Non-Small Cell Lung Cancer
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2023-509629-36-00
9
2025-10-29
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
-
2024-519081-49-00
4
2025-10-28
Moderate to severe atopic dermatitis
-
2025-520694-39-00
4
2025-10-24
Metastatic or locally advanced irresectable (stage IV) gastric cancer
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes